View this email in your browser ([link removed])
[link removed]
The Hidden Dangers Of CMS' Drug Pricing Regulation
Forbes | January 22, 2025 | Wayne Winegarden
CMS recently announced the next 15 drugs that will be subject to price negotiations under the Inflation Reduction Act of 2022 (IRA). These are negotiations in name only because CMS can levy penalties on any manufacturer that fails to comply with the process. Since the penalties include an excise tax up to 95% of a drugs total U.S. sales revenue, the law essentially empowers CMS to set its desired prices (e.g. price controls).
Price controls discourage R&D spending. With less investment devoted toward discovering and developing new medicines, the pace of innovation will dramatically slow. Fewer breakthrough medications will reach the market harming patients who are depending on the development of these new drugs for their health and well-being.
Read here . . . ([link removed])
Canada's Healthcare System Has No Place In America
Forbes | Sally Pipes | January 21, 2025
When Justin Trudeau announced earlier this month that he would resign as prime minister of Canada, Donald Trump was ready with one of his go-to jokes.
“Many people in Canada LOVE being the 51st State,” then President-elect Trump posted on social media... “Together, what a great Nation it would be!!!”
As a native-born Canadian who has been proud to call the United States home for many years, I am well-suited to evaluate that claim. And I’m sorry to say that, things being how they are, the United States is better off leaving Canada be.
Read more... ([link removed])
------------------------------------------------------------
Good Intentions Cannot Justify A Flawed Federal Health Policy
RealClearHealth | Daniel M. Kolkey | January 21, 2025
A government program may be the “nearest thing to eternal life we’ll ever see on this earth,” warned Ronald Reagan – even if it is flawed.
Section 340B of the Public Health Services Act is a case in point. Enacted over 30 years ago, that law enables certain healthcare facilities, including public hospitals and community health centers, to purchase prescription drugs at discounted prices in order to support underserved communities. As a result, every year, American hospitals receive about $50 billion in federally mandated discounts from drug companies. And drug companies must offer these discounts if they want to participate in Medicaid — the government insurance program for low-income Americans.
What could possibly go wrong?
Read more... ([link removed])
[link removed]
============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Instagram ([link removed])
** Website ([link removed])
Copyright © 2024 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116
** ([link removed])
Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.
